CDC6 Antibody

What is CDC6 and why is it important in research?

CDC6 (Cell Division Cycle 6) is a replication licensing factor involved in the initiation of DNA replication. Beyond this primary role, CDC6 participates in checkpoint controls ensuring DNA replication completion before mitosis initiation . Research over the past decade has revealed CDC6's additional function in transcriptional regulation, which has been linked to human cancer development . CDC6 is particularly significant in research because it represents a molecular switch with critical roles in both normal cell cycle progression and pathological processes, making CDC6 antibodies valuable tools for investigating these mechanisms.

What are the key considerations when selecting a CDC6 antibody for research?

When selecting a CDC6 antibody, researchers should consider:

• Epitope specificity: N-terminal antibodies (like ab188423) target amino acids 1-350 of human CDC6 .

• Species reactivity: Confirm the antibody works in your model system (human, mouse, etc.).

• Application compatibility: Verify suitability for your intended applications (IP, WB, ICC/IF).

• Validation evidence: Review available validation data, including western blot bands at the expected molecular weight (63 kDa for CDC6) .

• Isoform detection: Ensure the antibody detects relevant CDC6 isoforms in your experimental context.

• Cross-reactivity profile: Examine potential cross-reactivity with related proteins.

Cross-reference these specifications with your experimental needs before selection.

How can I validate a CDC6 antibody before using it in critical experiments?

A systematic antibody validation approach should include:

• Positive and negative controls: Use cell lines with known CDC6 expression levels, including CDC6-knockout or CDC6-depleted cells (via siRNA) as negative controls.

• Multiple detection methods: Verify specificity across different techniques (WB, IF, IP).

• Epitope blocking: Pre-incubate the antibody with the immunogen peptide to confirm signal specificity.

• Molecular weight verification: Confirm the detected band matches CDC6's predicted size (63 kDa) .

• Subcellular localization: Verify nuclear localization pattern consistent with CDC6's known distribution.

• Reproducibility testing: Ensure consistent results across multiple experiments.

Document all validation steps thoroughly according to reporting guidelines for research antibody use.

What are the optimal protocols for using CDC6 antibodies in immunohistochemistry?

For optimal CDC6 detection in tissue samples:

• Fixation: Use 4% paraformaldehyde for 10 minutes to preserve epitope accessibility .

• Antigen retrieval: Heat-mediated retrieval in citrate buffer (pH 6.0) is generally effective.

• Blocking: Use 3% BSA in PBS with 0.5% Triton X-100 for 30 minutes to reduce background .

• Primary antibody: Dilute CDC6 antibody (typically 1:500-1:1000) and incubate overnight at 4°C .

• Detection system: Use appropriate secondary antibodies and visualization methods based on your experimental design.

• Counterstaining: DAPI (1 μg/ml) is effective for nuclear visualization .

• Controls: Include both positive controls (known CDC6-expressing tissues) and negative controls (primary antibody omission).

When analyzing results, establish clear scoring criteria. In a cervical cancer study, cases were classified as positive when >5% of cells showed nuclear CDC6 staining, with expression means of 154.76 in SCC and 156.18 in HSIL compared to 39.09 in normal tissues .

How should I optimize CDC6 antibodies for western blotting applications?

For optimal western blot detection of CDC6:

• Sample preparation: Use RIPA buffer with protease inhibitors for cell lysis.

• Protein loading: Load 20-50 μg of total protein per lane.

• Gel percentage: Use 8-10% SDS-PAGE gels for optimal separation around CDC6's 63 kDa size .

• Transfer conditions: Transfer to PVDF membrane at 100V for 1 hour or 30V overnight.

• Blocking: 5% non-fat milk in TBST for 1 hour at room temperature.

• Primary antibody: Dilute CDC6 antibody 1:1000 in blocking buffer and incubate overnight at 4°C .

• Washing: 3-5 washes with TBST, 5 minutes each.

• Secondary antibody: Appropriate HRP-conjugated secondary antibody for 1 hour at room temperature.

• Detection: Use enhanced chemiluminescence (ECL) detection system.

When troubleshooting, note that CDC6 protein levels fluctuate during the cell cycle, so synchronization may be necessary for consistent results.

What are effective immunoprecipitation protocols when studying CDC6 protein-protein interactions?

For successful CDC6 immunoprecipitation:

• Cell lysis: Use gentle lysis buffer (150 mM NaCl, 50 mM Tris pH 7.5, 1% NP-40, 0.5% sodium deoxycholate, protease inhibitors).

• Pre-clearing: Incubate lysate with protein A/G beads for 1 hour at 4°C.

• Antibody binding: Incubate 1-2 μg of CDC6 antibody with 500 μg-1 mg of pre-cleared lysate overnight at 4°C.

• Immunoprecipitation: Add protein A/G beads for 2-4 hours at 4°C.

• Washing: Perform 3-5 stringent washes with lysis buffer.

• Elution: Use gentle elution conditions (sample buffer without DTT or BME at room temperature) to avoid co-precipitating proteins dissociation.

• Analysis: Western blot analysis with CDC6 antibody diluted 1:1000 .

When assessing results, compare with appropriate controls including non-immune IgG precipitation control and input samples (5-10% of starting material) . Published protocols demonstrate successful CDC6 immunoprecipitation from HeLa whole cell lysates using CDC6 antibody.

How is CDC6 expression altered across different cancer types?

CDC6 expression demonstrates significant upregulation across multiple cancer types:

These expression patterns make CDC6 a potential biomarker for cancer diagnosis and prognosis across multiple malignancies.

What methodologies are used to study CDC6's role in epithelial-to-mesenchymal transition?

To investigate CDC6's involvement in EMT:

• Inducible expression systems: Create epithelial cell models with inducible CDC6 overexpression to observe phenotypic changes .

• Flow cytometric analysis: Monitor EMT-associated markers (CD24 low/CD44 high) in cells overexpressing CDC6. This configuration is associated with stem-like features .

• E-cadherin monitoring: Track loss of epithelial marker E-cadherin via immunoblotting or immunofluorescence following CDC6 modulation .

• Chromatin immunoprecipitation (ChIP): Assess CDC6 recruitment to E-box, CTCF binding sites or origins of replication within EMT-related gene promoters .

• Epigenetic modifier analysis: Investigate recruitment of Polycomb group proteins (e.g., BMI1), histone deacetylases, and histone methyltransferases to CDC6-bound genomic regions .

• Long-term phenotypic tracking: Monitor cells through the stages of senescence barrier activation and subsequent escape, capturing the complete spectrum of epithelial carcinogenesis .

This multifaceted approach has revealed CDC6's mechanistic role in promoting EMT through transcriptional repression of key tumor suppressor genes.

How can CDC6 antibodies be utilized to study DNA replication stress in cancer cells?

CDC6 antibodies are valuable tools for investigating replication stress:

• Immunofluorescence co-localization: Combine CDC6 antibodies with γH2AX and 53BP1 antibodies to visualize replication stress-induced DNA damage foci. CDC6 overexpression results in replication fork stalling, collapse, and DNA damage with subsequent DDR activation .

• Replication origin licensing analysis: Use CDC6 antibodies to track origin licensing impairment following CDK4/6 inhibition, which can cause replication stress through downregulation of replisome components .

• Flow cytometry: Combine with EdU incorporation to detect re-replication (cells with DNA content >4n), a form of replication stress induced by CDC6 overexpression .

• Alkaline comet assay: Correlate CDC6 expression with DNA damage using this technique, which has demonstrated increased DNA damage following CDC6 induction .

• Chromatin fractionation: Employ CDC6 antibodies to track chromatin-bound versus soluble CDC6 to understand licensing dynamics.

• Proximity ligation assays: Detect CDC6 interactions with components of the pre-replication complex during replication stress.

These approaches have revealed that CDC6 overexpression induces replication stress that can lead to genomic instability, contributing to cancer development.

How is CDC6 involved in transcriptional regulation, and what methods can detect this activity?

CDC6's emerging role in transcriptional regulation can be studied using:

• Chromatin immunoprecipitation followed by sequencing (ChIP-seq): Map genome-wide CDC6 binding sites to identify direct transcriptional targets. This has revealed CDC6 recruitment to genomic loci containing E-boxes, CTCF binding sites, and/or origins of replication .

• Gene expression analysis: RNA-seq following CDC6 modulation has identified de-regulated genes, showing both repression and activation of different gene sets .

• Reporter assays: Measure E-box motif-dependent transcriptional activity following CDC6 manipulation, which has demonstrated CDC6's ability to abrogate c-Myc transcriptional activity by competing with Max binding .

• Co-immunoprecipitation: Detect CDC6 interactions with transcription factors such as c-Myc, which has shown CDC6 can bind to the C-proximal region of c-Myc .

• Histone modification analysis: Examine changes in histone acetylation and methylation at CDC6-bound promoters to understand the mechanism of transcriptional repression, revealing recruitment of histone deacetylases and histone methyltransferases .

Research has demonstrated that CDC6 acts as a transcriptional repressor for genes like E-cadherin and INK4/ARF, contributing to EMT and cancer progression through chromatin remodeling and heterochromatinization.

What are the challenges and solutions when studying CDC6 post-translational modifications?

Studying CDC6 post-translational modifications presents several challenges:

• Phosphorylation state detection:

  • Challenge: Multiple phosphorylation sites affect CDC6 stability and localization.

  • Solution: Use phospho-specific CDC6 antibodies or Phos-tag SDS-PAGE followed by western blotting with standard CDC6 antibodies.

• Ubiquitination detection:

  • Challenge: Ubiquitinated CDC6 species can be rapidly degraded.

  • Solution: Pretreat cells with proteasome inhibitors (MG132) before lysis and immunoprecipitation.

• Nuclear-cytoplasmic shuttling:

  • Challenge: CDC6 localization changes throughout the cell cycle.

  • Solution: Combine cell synchronization with subcellular fractionation and compartment-specific western blotting.

• Cell cycle variation:

  • Challenge: CDC6 modifications vary significantly across cell cycle phases.

  • Solution: Use cell synchronization methods (serum starvation, thymidine block) followed by time-course analysis.

• Low abundance modified forms:

  • Challenge: Some modified forms exist transiently or at low levels.

  • Solution: Employ enrichment strategies such as immunoprecipitation before western blotting.

These approaches help reveal how post-translational modifications regulate CDC6's multiple functions in replication and transcription.

How can CDC6 be explored as a predictive biomarker for immunotherapy response?

To investigate CDC6 as an immunotherapy response predictor:

• Expression correlation analysis: Analysis of 25 immunotherapy cohorts has shown that CDC6 has predictive value with an AUC higher than 0.5 in nine immunotherapy cohorts, demonstrating higher predictive power than B-Clonality and TMB in some contexts .

• Immune infiltration analysis: Use computational methods like TIMER, CIBERSORT, xCell, McP-Counter, and EPIC to analyze correlation between CDC6 expression and infiltration of 12 immune cell types, including B cells, CD8+ T cells, CD4+ T cells, and others .

• TIDE prediction: Use the Tumor Immune Dysfunction and Exclusion (TIDE) computational method to predict treatment responses to CDC6-based on core immunotherapy and CRISPR screening experiments .

• Comparative biomarker analysis: Compare CDC6's predictive power against established biomarkers like TMB, MSI-Score, CD274, CD8, IFNG, and T-Clonality .

• Combination marker development: Integrate CDC6 expression with other markers to develop composite predictive signatures with enhanced accuracy.

Current data suggests CDC6 may have significant predictive value for immunotherapy response in specific cancer contexts, though further validation is required.

What are common problems when using CDC6 antibodies and how can they be resolved?

Common CDC6 antibody issues and solutions include:

• High background in immunostaining:

  • Issue: Non-specific binding to cellular components.

  • Solution: Increase blocking time to 30 minutes with 3% BSA in PBS with 0.5% Triton X-100 . Titrate primary antibody concentration and reduce incubation time.

• Multiple bands in western blot:

  • Issue: Splice variants, degradation products, or cross-reactivity.

  • Solution: Use freshly prepared lysates with protease inhibitors. Verify bands against positive controls and expected molecular weight (63 kDa) .

• Weak or absent signal:

  • Issue: Low CDC6 abundance or epitope masking.

  • Solution: Increase protein loading to 50 μg. For IHC/IF, optimize antigen retrieval methods. Consider cell cycle synchronization, as CDC6 levels fluctuate throughout the cell cycle.

• Inconsistent results between experiments:

  • Issue: Cell cycle-dependent expression variations.

  • Solution: Standardize cell culture conditions and consider cell synchronization protocols.

• Poor immunoprecipitation efficiency:

  • Issue: Weak antibody-antigen interaction or harsh lysis conditions.

  • Solution: Use gentler lysis buffers and optimize antibody-to-lysate ratios. Compare results with validated control samples .

Rigorous antibody validation and optimization for specific experimental conditions are essential for reliable CDC6 detection.

How should researchers interpret contradictory results when studying CDC6 across different cancer models?

When facing contradictory CDC6 findings across cancer models:

• Context-dependent function assessment:

  • CDC6 may have different roles depending on cancer type and genetic background. Evaluate CDC6 in the specific molecular context of each model.

  • Compare CDC6 function in the presence or absence of key tumor suppressors like p53, as CDC6 overexpression activates the p53 pathway in some contexts .

• Methodological reconciliation:

  • Compare antibody specificity and experimental approaches across studies.

  • Standardize quantification methods for CDC6 expression across different techniques.

• Cell line heterogeneity analysis:

  • Characterize the baseline genetic and epigenetic landscape of each model.

  • Account for variations in p53 status, Rb pathway integrity, and DNA damage response mechanisms.

• Time-dependent effects consideration:

  • CDC6 may have biphasic effects—initially triggering anti-tumor barriers like senescence, followed by emergence of aggressive clones with EMT features after escape .

  • Design time-course experiments to capture these dynamic effects.

• Integration with clinical data:

  • Correlate in vitro findings with patient data to assess clinical relevance.

  • Compare CDC6 expression patterns across different cancer stages and subtypes.

This multifaceted approach can reconcile apparently contradictory findings by revealing context-specific CDC6 functions.

What are the best approaches for quantifying CDC6 expression in tissue microarrays for clinical correlations?

For rigorous CDC6 quantification in tissue microarrays:

• Standardized staining protocol:

  • Maintain consistent fixation, antigen retrieval, and staining conditions across all samples.

  • Process all samples in a single batch when possible to minimize technical variation.

• Multi-tier scoring system:

  • Implement labeling index (LI) scoring as used in cervical cancer studies, where the mean LI for normal tissues was 39.09 compared to 154.76 for SCC .

  • Consider both staining intensity (0-3 scale) and percentage of positive cells.

• Automated image analysis:

  • Use digital pathology software with validated algorithms for nuclear protein quantification.

  • Validate automated scoring against manual pathologist assessment.

• Reference controls:

  • Include calibration tissues with known CDC6 expression levels on each array.

  • Use these as internal standards to normalize between batches.

• Statistical analysis:

  • Apply Bonferroni multiple comparison correction when analyzing multiple tissue types.

  • Use appropriate statistical tests based on data distribution (parametric vs. non-parametric).

• Clinical correlation:

  • Generate Kaplan-Meier survival curves stratified by CDC6 expression levels.

  • Perform multivariate analysis to control for confounding clinical variables.

Studies have shown progressive increases in CDC6 expression from normal tissue through premalignant lesions to invasive cancers, with significant prognostic implications .